This article contains observations and historical considerations on cancer and complementary and alternative medicine (CAM) in Italy, a country that has a great tradition in medical research, going back to the Renaissance. However, Italy does not have a strong tradition of using CAM approaches in the treatment of cancer. While surveys show that the Italian population is eager to learn more about CAM, the medical profession there is largely dismissive of these methods. In 1997-1998, the notorious Luigi Di Bella affair occurred in Italy, when a professor of physiology at Modena proposed a nonconventional approach to cancer treatment, based on the off-label use of somatostatin. This treatment found champions in the media and general public but was opposed by most of the medical profession. Although clinical trials later demonstrated that it had no efficacy, the affair divided Italian public opinion and nearly brought down the national government. Italy no longer has prominent proponents of nonconventional treatments in cancer. However, it continues to have innovative scientists who do important work that is consonant with a CAM approach. This article considers the work of 3 such scientists: Paolo Lissoni, MD, of Monza (Milan), who has carried out numerous clinical trials with the pineal hormone melatonin; Giancarlo Pizza, MD, of Bologna, who has done extensive work on the use of transfer factor and other immunomodulators in the treatment of renal cell and other kinds of cancer; and Aldo Mancini, MD, of Naples, who has isolated a mutated form of Mn-SOD-2 from the growth medium of a unique liposarcoma cell line. These scientists have introduced some flexibility into a rigid state-run hospital system by offering patients innovative treatment options in the context of approved clinical trials.
In November 2003, I visited Italy to speak at a conference on cancer prevention at the Santa Famiglia Hospital in Rome. I also toured the country to visit with clinicians doing innovative work in the field of cancer treatment. What follows are some of my observations on cancer and complementary and alternative medicine (CAM) in this ancient country.
Italy has a long and venerable tradition in medicine. The West's first medical schools were established in Salerno (10th-century AD) and Bologna (11thcentury AD), and during the late medieval period, Italy was in the vanguard of medical research. The science of anatomy had its origins in Renaissance Italy, and its early pioneers-Malpighius, Fallopius, Eustachius, and many others-remain as foundational to modern medicine as Michelangelo and Leonardo Da Vinci are to the world of art.
Indeed, as the historian of cancer Michael Shimkin, MD, has pointed out, modern medicine as a whole could claim Italy as its birthplace and 1543 AD as its birth date since this was the year in which Andreas Vesalius, then a professor at the University of Padua, wrote the first complete textbook of human anatomy, De Humani Corporis Fabrica. 1 Italian physicians were among the first to document the ravages of cancer and to devise plausible treatments for it: the first descriptions of stomach cancer came from Antonio Benivieni (1443-1502 AD) of Florence, and Gabriele Fallopius (1523-1562 AD) of Pisa and Padua was one of the first to propose the use of arsenic-containing pastes for cancer. (Four centuries later, the US Food and Drug Administration approved-in what it called "record time"-the use of arsenic as an internal treatment for cancer. 2 ) This distinguished tradition continues. In the 20th century, Italian scientists made significant contributions to oncology. In the mid-1960s, for example, scientists from an Italian pharmaceutical company, Farmitalia, isolated Streptomyces peucetius from a rare species of fungus that was found growing in a ruined tower overlooking the shores of the Adriatic Sea. 3 This organism yielded the first anthracycline drugs, daunorubicin and doxorubicin. Because of the seaside location of the original discovery, the latter drug was given the trade name Adriamycin. This compound, and related anthracyclines, are now among the most widely used chemotherapeutic agents in the world, especially for the treatment of metastatic solid tumors. 4 Prominent 20th-century Italian oncologists include Umberto Veronesi, MD, who for 18 years was director of the Istituto Nazionale per lo Studio e la Cura di Tumori (Italian National Cancer Institute) in Milan. He was also director of the European Institute of Oncology and, from 1978 to 1982, president of the International Union Against Cancer. Among many others, there is also Gianni Bonadonna, MD, chief emeritus of medical oncology at Milan's cancer institute. The author of more than 400 MEDLINE-indexed articles on cancer, Bonadonna devised the combination chemotherapy regimen known as CMF for breast cancer, a regimen that bears his name and is still in use today. 5 Altogether, Italy has had a long, proud record in the field of cancer therapy.
Cancer and Public Health in Italy
Cancer is a major health problem in Italy, as it is in the United States and other industrialized countries. In general, cancer incidence rates in Italy are similar to those in the United States. But the age-adjusted mortality rate among Italian men exceeds that of American men. The reasons that male cancer rates are so high may be in part attributable to the fact that the rates of smoking-related cancers are high among Italian men. Italy's male mortality rate is almost identical to Germany's (177.6 per 100,000), which presently ranks 16th in the world. The female mortality rate (98.86 per 100,000) is less than Germany's (116.9) and closer to that of France (98.0), which has a fairly low ranking of 30th in the world.* , 6 As I shall explain, there are dietary and lifestyle factors that are pulling Italy in contradictory directions in terms of cancer incidence.
CAM Approaches on 2 Sides of the Alps
Despite its historical love affair with innovation, Italy does not have a strong tradition of CAM approaches to cancer. The reasons for this are complex, but certainly one factor may be a historically entrenched distrust of unorthodox approaches to medicine. During the Renaissance and early modern period, Italy was overrun with quacks. So outrageous were their claims and activities that they received a special name, ciarlitani, derived from the Italian word ciarlare, meaning to prattle, and it is from this root that we get the English word charlatan. †,7 Italian charlatans, or mountebanks (another word of Italian derivation), were an "export crop," and many found their way to England and other countries during this period. The fact that they placed a heavy emphasis on selling antidotes tended to reinforce northern prejudices against Italians, who were seen as Borgian poisoners and Popish conspirators. 8 Eventually, all would-be charlatans copied the Italian model. According to the late Professor Roy Porter, in his outstanding book Quacks: Fakers and Charlatans in English Medicine,
The traditional quack in renaissance Europe, modeling himself on the Italian ciarlatani, prefaced his act by defining a public space, a theatre where his word was king. The mountebank performed from a mobile stage or improved rostrum to give himself the advantage of height-or, like a general, declaimed from horseback, with the additional advantage of a ready get-away. 8(p90) In the late 19th century, a wealthy but peculiar aristocrat, Count Cesare Mattei (1809-1896) of Bologna, developed a unique system of treatment called L'elettromeopatia (electro-homeopathy) in which he extracted from certain plants the "active principles," which formed the agents of his new Materia Medica. 9 For a while, this constituted a prominent nonconventional challenge to orthodox medicine, but it eventually lapsed into obscurity, along with other such systems. ‡10 By the mid-20th century, the Italian medical profession had reestablished control. There have, of course, been challenges to the status quo of allopathic medicine since then, but in general, the Italian medical establishment has been quite successful in limiting medical treatment-and in particular cancer treatment-to those procedures recommended by academic medicine and in branding nonconventional practices as charlatanism, according to a comprehensive work on this topic, Mountebanks and Medicasters: A History of Italian Charlatans from the Middle Ages to the Present. 11 right of self-determination. "Clinicians must respect the autonomy of cancer patients in their quest for appropriate therapies, and assist rather than direct their process of therapy-seeking," wrote Canadian oncologists in 1999. 12 Since 1998, it has been the official policy of the American Society of Clinical Oncology (ASCO) that cancer care must be "responsive to the patient's wishes and to the parents' wishes, if the patient is a child." 13 Historically, the Italian medical profession has been slower to shed its paternalistic traditions, and correspondingly, Italian patients have tended to be somewhat submissive in the face of medical authority. (I was once told by a prominent American researcher that the US National Cancer Institute [NCI] performed clinical trials in Italy because "Italian patients will do anything their doctors tell them to do.") Italy has among the oldest populations in the world, with 18.1% of Italians having celebrated at least their 65th birthday. 14 It also has a relatively low rate of high school and college graduates and limited access to information on alternatives-all of which have retarded the development of medical consumerism.
This institutionalized paternalism has to a certain extent been reinforced by the state's "cradle to grave" medical system, initiated in 1978, which offers little in the way of choice and requires few decisions on the part of the patient. Although the system has been frequently criticized, 15, 16 essentially most conventional treatment is provided, as long as the patient submits to the standard treatments that are recommended. In Italy, however, there is a wide gulf between orthodox and CAM approaches. Italy lags far behind the United States and northern European countries in the development and acceptance of nonconventional cancer treatments.
Countries such as Britain, with stronger laissez-faire traditions in medicine, generally exhibit more tolerance for unorthodox medical practices. Historically, as Professor Roy Porter has made clear, flamboyantly unconventional practitioners sometimes attained the highest degree of recognition and success, and the gulf between orthodox and unorthodox medicine gradually narrowed in that country during the 18th and early 19th centuries. 8 Germany leads the world in terms of the number and variety of nonconventional practices and clinics, many of them located in its more than 100 picturesque spa towns, whose very existence is consonant with a CAM approach to health. Since legislation enacted at the national level in 1976, Germany has pursued a course of "medical pluralism," encouraging the regulated growth of various nonconventional medical systems. There are CAM-oriented cancer organizations, academic institutes, medical schools, and even statesponsored hospitals in this, the birthplace of naturopathy and homeopathy. 17 Clinics on the German model are now also found in Denmark, Switzerland, Austria, among others.
Even the United States, the bastion of chemotherapy and radiation-oriented oncology, has witnessed profound changes in recent years. These changes were accelerated by the creation, in the early 1990s, of the National Center for Complementary and Alternative Medicine (originally the Office of Alternative Medicine) of the National Institutes of Health (NIH). The NCI, once a firm opponent of CAM, has established an Office of Cancer Complementary and Alternative Medicine (OCCAM) to investigate such methods with objectivity. Harvard University researchers who were themselves involved in these changes have pointed to the emergence of "postmodern medical diversity" in America and a shift "in medicine's institutional authority in a consumer-driven health care environment." 18 In the United States, as these same researchers have pointed out, an estimated 44% of the population used at least one CAM therapy in 1997, making an estimated 629 million visits to CAM providers. 19 This exceeded the total visits to all regular US primary care physicians. 20 By contrast, between 1997 and 1999, only 15.6% of the Italian population used some form of unconventional therapy, that is, approximately one third of American usage. Herbal medicine was used by only 4.8%. Although such usage may be increasing, and one sees herbalists and homeopathic pharmacies in all the big cities, Italy still ranks "among the 'light' users [of CAM] compared with other European countries." 21 By all accounts, then, the knowledge and use of CAM in Italy is low. There are no CAM treatment, education, support, or information services listed in Third Opinion, an international directory of alternative therapy centers. 22 None of the physicians listed in another popular work, Alternative Medicine: The Definitive Guide to Cancer, practices in Italy. 23 During my trip, I visited with several practitioners who are well disposed toward CAM but all of whom worked at state hospitals. None had established an independent clinic or hospital-a common occurrence, by contrast, in Germany. Indeed, while all the clinicians whom I visited in Italy were doing noteworthy work, it would be difficult to classify any of them as a CAM practitioner, even using that term loosely.
Rather, most are innovative immunotherapists, who have developed techniques that could find ready applications in both CAM and conventional clinics around the world. In the context of Italy, however, they do represent "alternatives" to the conventional brand of oncology that is universally practiced in Italian hospitals. There has to date been no concerted attempt in Italy to integrate such immunotherapeutic methods into a holistic mindbody program for cancer patients.
Yet the situation is definitely changing. One indication of this is that when conventional oncologists were asked about their patients' CAM usage, they estimated that 84% were using some form of CAM. 24 This was clearly an overestimate, but it did reflect their awareness of patients' burgeoning interest in this topic: a 1999 survey showed that 63% of Italian cancer patients would in fact like to try "unproven treatments" in their search for a cure. 25, 26 However, as a rule, Italian cancer patients have limited access to CAM treatments, and with Internet use in Italy being among the lowest in Europe, even obtaining information about CAM treatments is difficult.
Not surprisingly, another survey in the 1990s concluded that "the level and the quality of the knowledge of CM [complementary medicine] of the oncologists interviewed were low. The oncologists could hardly be helpful for their patients in dealing with therapies different from conventional medicine." 27(p539) The authors of this survey were themselves conventional epidemiologists. Italians seeking CAM cancer care are therefore more or less obliged to go to another country, such as Germany, for alternative treatments or to patch together self-treatment regimens with information gained through various nonconventional sources.
A population eager to learn about CAM cancer treatments combined with a medical profession that is largely ignorant (or dismissive) of these same methods amounts to a prescription for conflict. And indeed in 1997-1998, just such a mutually destructive conflict occurred. I refer to the celebrated Di Bella affair, which shook all of Italy for more than a year and very nearly brought down the national government.
The Di Bella Affair
Dr Luigi Di Bella was a longtime professor of physiology at Modena University. He died in July 2003 at the age of 91. 28 For some years, Di Bella quietly used an anticancer regimen of his own devising, which con-sisted of a combination of the drug somatostatin and vitamins, retinoids, melatonin, and bromocriptine. 29 Somatostatin is a standard drug used for the treatment of the symptoms of carcinoid-type malignancies, 30 but it is not standard practice to use it in the treatment of nonproductive tumors.
The affair that bears Di Bella's name was precipitated in December 1997 by the case of a pediatric cancer patient in Lecce, a town in Puglia, whose parents sought to have him treated by Di Bella's method. The medical authorities refused to administer such an unconventional treatment, and the case was brought before the courts. Unexpectedly, the judges sided with the parents and ordered the local oncologists to administer the treatment and the health authorities to pay for it. The case came to the attention of the media and became a national scandal. Although the child died in February 1998, public interest in the Di Bella treatment continued to build. A growing number of patients and their supporters organized demonstrations calling for medical freedom of choice. Various newspapers, magazines, and television stations focused intently on the case and its far-reaching implications concerning who should properly make treatment decisions in Italian society. 31 "You have no idea what kind of pressure we were under," said Dr Dino Amadori, president of the Italian Oncological Society. "Society was set to explode. Our office was getting death threats." 32 In February 1998, after demonstrations in St. Peter's Square, even Pope John Paul II became involved. In a Vatican address, he called for a reconciliation between Di Bella's followers and government officials. 32 Italy is a highly politicized society, and many of the most emotional outpourings at this time had manifestly political overtones. The government at the time was a center-left coalition, whereas the journals that fanned the flames were mostly aligned with the rightwing opposition. Coincidentally or not, the largest owner of television stations, newspapers, and magazines in Italy, Silvio Berlusconi, became the prime minister of the next (and present) government.
It was a measure of the intensity of public interest in this case that in January 1998, the minister of health, Ms Rosy Bindi, was compelled to publicly debate Di Bella on television. Nine million Italians (or 18.2% of the population over the age of 14 years) watched this historic confrontation. Soon afterward, it was announced that clinical trials of the Di Bella regime would be carried out in various public hospitals. One of Italy's most famous oncologists, the aforementioned Umberto Veronesi, MD, was appointed copresident of the official commission set up by the Ministry of Public Health for the testing of Di Bella's claims.
Patients who chose the Di Bella treatment were entered into 9 phase II, open-label studies at a number of cancer centers. They included patients with cancers of the breast, lung, pancreas, colon, brain, head and neck, and non-Hodgkin's lymphomas, who were unresponsive to conventional treatments or who had refused established treatments. Patients with more advanced cancers were eligible for another trial that was intended to follow a total of 2600 patients.
In early July 1998, the first results of a clinical trial from the Lombardy region were released. Out of 333 evaluable patients, only 1 (0.3%) showed a partial response, and one third of patients showed no change. Half the patients had local growth of their tumors, and 14% had new metastatic involvement. Adverse effects (nausea, vomiting, diarrhea, neurological signs) were reported in 23% of patients, and 3.3% had to stop the treatment because of adverse effects.
By the end of July 1998, 4 of the state-sponsored trials had been concluded. None of the 136 enrolled patients had shown any objective improvement. Nine percent had stable disease during treatment, while 50% progressed, 25% died, and 13% abandoned the regimen because of side effects. Three percent were not available for evaluation. A final tabulation of 386 patients as of October 31, 1998 , showed that no patient had had a complete remission. Three patients achieved partial remission: 1 of the 32 patients with non-Hodgkin's lymphoma, 1 of the 33 patients with breast cancer, and 1 of the 29 patients with pancreatic cancer. At the second examination, 12% (47) of the patients had stable disease, 52% (199) progressed, and 25% (97) died. 33 These results were understandably interpreted as proving that the Di Bella treatment had failed. But Di Bella was unrepentant. He was quoted in the New York Times as saying that the clinical trials had been rigged by oncologists jealous of his success. Many ordinary Italians agreed with him: a poll taken after the results were announced showed that 67% of Italian adults continued to have faith in the Di Bella treatment.
Some scientists were skeptical of Di Bella's treatment and critical of the manner in which it had been promoted, but they had only praise for the man himself, as scientist, teacher, and humanitarian. Eventually, however, the media lost interest in the affair and moved on to other sensational imbroglios.
The Di Bella affair demonstrated both a pent-up interest in nontraditional cancer treatments on the part of the Italian public and an unsuspected degree of cynicism over the "cancer establishment." Among the many negatives were (1) the fact that treatment failed to produce any significant positive results in these clinical trials, (2) this failure served to discredit alternative treatments in general, and (3) the affair reinforced the position of conventional medicine as the exclusive source of correct information on cancer treatment.
Most of the published articles on the Di Bella affair have excoriated the losing side and used the opportunity to attack alternative treatments in general. As an illustration of this attitude, Dr Gianfillipo Bertelli, a medical oncologist from Genoa, used his report on Di Bella at the Quackwatch Web site to excoriate CAM cancer treatments in general:
As with other unorthodox cancer treatments, the controversy over Di Bella's therapy caused unnecessary suffering for patients and their families. Media fervor, judicial decisions, and public pressure compelled the government to sponsor clinical trials despite the lack of scientific evidence. Predictably, results were negative. The trials helped calm public hysteria and kept some cancer patients from abandoning effective treatments. This was achieved, however, with considerable waste of precious government resources. 34 On the positive side, the affair raised to prominence the issue of nonconventional treatments in a country that until then had had little exposure to such ideas. But in the aftermath of this affair, with its polarizing effect, proponents of unusual but scientifically reputable treatments became more fearful of speaking out about their own treatments. Each was afraid of becoming "the next Di Bella."
A Visit to 3 Hospitals
My first stop on this voyage was the New San Gerardo Hospital (Ospedale S. Gerardo dei Tintori) in Monza, an industrial suburb of Milan. What is called in Monza the "new" hospital is now 2 decades old. It is a huge structure that resembles a typical American Veterans' Administration hospital. New San Gerardo seemed adequately equipped but manifestly understaffed. Dr Paolo Lissoni, the head of oncology, was clearly overworked. He explained that cutbacks in staffing have left him and his coworkers with inadequate time to do both clinical and academic work. He had to interrupt our discussion on several occasions to attend to urgent patient needs.
Despite being so chronically overworked, over the past 20 years, Lissoni's output has been prodigious. He is the author of more than 250 peer-reviewed, PubMed-listed articles, 33 of which are randomized controlled trials (RCTs). He had 9 PubMed publications in 2003 alone, most of those concerning phase II or III clinical trials. It is especially impressive that all of this writing and research has been squeezed into the interstices of such a very busy clinical schedule.
Coincidentally, some of Lissoni's earlier papers were coauthored with Di Bella, who shared Lissoni's interest in the role of melatonin in the control of biological systems in general and cancer in particular. [35] [36] [37] However, unlike Di Bella, Lissoni's clinical practice has taken place entirely in the context of the public hospital and clinical trial system and has never become a matter of public controversy. There has been no attempt to set up a stand-alone private practice, much less to mount a militant challenge to the orthodox oncologists' dominance over the choice of treatments. Within the context of numerous institutional review board-approved clinical trials, however, Lissoni has been able to do highly innovative work, with clear implications for those who treat cancer with CAM around the world.
Most of Lissoni's published work concerns the use of the pineal gland hormone melatonin in the treatment of cancer. Melatonin was first isolated and characterized by Dr Aaron B. Lerner of Yale University in 1958. Although primarily known as a regulator of circadian rhythms, melatonin has been shown (mainly through Lissoni's work) to exert anticancer activity through several concurrent mechanisms. These include antiproliferation, stimulation of anticancer immunity, modulation of oncogene expression, and antioxidant and antiangiogenic effects. 38 Lissoni has described cancer as an "immune-endocrine disorder." His interest in melatonin came about not because of some empirical search for an anticancer supplement, but because of his deep conviction that cancer is fundamentally a disease of the interrelated immune and endocrine systems.
When patients are in a state of depressed immunity, he says, they cannot destroy their cancers. Most patients with advanced cancer have clear deficiencies of immunological function. Typically, they register low levels of the anticancer cytokine, interleukin-2 (IL-2), while exhibiting an increase in levels of proinflammatory cytokines IL-6 and IL-10. They also frequently display reduced functioning of the pineal gland and a decrease in production of its characteristic peptide hormone, melatonin.
Lissoni has demonstrated that under experimental conditions, this neuroendocrine disorder actually precedes the development of clinical cancer. Every condition that diminishes the healthy functioning of the pineal gland and its output of melatonin, he says, thereby increases the risk of cancer. When asked about causes of this malfunction of the "master gland," and therefore of cancer itself, Lissoni singled out electromagnetic field emissions, chronic stress, and mental depression. Such malfunctions, he says, almost always have prognostic and physiological significance in regard to the development of cancer.
The basis of Lissoni's research approach has been to restore a state of health by using the same biologically active substances that are found to be diminished in the cancerous state. He has experimented with many potentially useful immunomodulators such as IL-2, tumor necrosis factor, naltrexone, and Lcarnitine. However, the major focus of his work for almost 2 decades has been the pineal hormones, of which melatonin is the best known. He is presently also investigating the use of certain plant products (notably aloe vera and Bach-style flower extracts) to produce anticancer or palliative effects.
Lissoni's work on melatonin is world renowned; in fact, his name has become virtually synonymous with melatonin research. To put this in perspective, out of 53 articles listed in MEDLINE/PubMed on the topic of melatonin in the treatment of cancer, 41 (77%) come from Lissoni's group in Monza. Of the 24 published articles on RCTs of melatonin in cancer treatment, Lissoni's group is responsible for 22 (92%). He has also presented more than a dozen abstracts at the ASCO meetings on this and related topics. In 2003, he was an invited speaker at a special meeting on the topic of melatonin, chronobiology, and cancer convened by OCCAM of the NCI. (The proceedings of this meeting are available on the Internet as a video Web cast from the NIH. 39 ) Obviously, when dealing with such a prodigious output, it is impossible to include, or even summarize, all the findings. I will therefore focus on a few of the most provocative RCTs of the past dozen years.
Non-small-cell lung cancer. In 1992, Lissoni's group found that adding melatonin to chemotherapy in metastatic non-small-cell lung cancer had a beneficial effect on survival. All the patients in question had progressed after first-line chemotherapy containing cisplatin. The study included 63 consecutive patients who were randomized to receive either melatonin (n = 31) or supportive care alone (n = 32). Patients were given 10 mg per day of melatonin in 1 pill taken at 7:00 PM. These patients were then followed for 1 year from the time of progression after chemotherapy and were compared to the control group that was randomized to receive supportive care alone. The percentage of both stabilization of disease and survival at 1 year was significantly higher in patients treated with melatonin than in those treated only with supportive care. In addition, not only was no drug-related toxicity noted, but on the contrary, treated patients "showed a significant improvement in performance status." 40 Solid tumors other than renal cell and melanoma. Two years later, Lissoni's group published an article in the British Journal of Cancer in which they showed that melatonin added to the standard immune stimulant IL-2 increased survival, even in cancers in which IL-2 was not thought to be effective. 41 This study was carried out in patients who had either locally advanced or metastatic solid tumors other than renal cell cancer and melanoma, 2 types that are well known to respond to IL-2. The study included 80 consecutive patients who were randomized to receive either IL-2 alone subcutaneously (3 million IU/d-1 at 8:00 PM 6 days a week for 4 weeks) or IL-2 plus melatonin (40 mg/d-1 orally at 8:00 PM every day starting 7 days before IL-2).
A complete response was obtained in none of the patients receiving IL-2 alone but in 3 of the 41 patients treated with IL-2 plus melatonin. A partial response was achieved in only 1 out of 39 patients treated with IL-2 alone but in 8 of the 41 patients treated with IL-2 plus melatonin. Thus, the overall objective response rate was 10 times greater (26.8%) in the melatoninadded group than in the group that received just IL-2.
(This group achieved a 2.6% response rate.) This difference was of course statistically significant (P < .001).
Survival at 1 year was also significantly higher in patients who were treated with both IL-2 and melatonin than in the IL-2-alone group (19 of 41 [46. 3%] vs 6 of 39 [15.4%], P < .05). Finally, the mean increase in lymphocyte and eosinophil numbers was significantly higher in the IL-2-plus-melatonin group than in patients treated with IL-2 alone. "This study shows that the concomitant administration of the pineal hormone MLT may increase the efficacy of lowdose IL-2 subcutaneous therapy," the authors concluded.
Brain metastases. In a study that appeared the same year in Cancer, the Lissoni group showed that the outcome for patients with unresectable brain metastases could also be improved by administration of melatonin. In the study, 50 patients were randomized to receive supportive care alone (steroids plus anticonvulsant agents) or to receive supportive care plus melatonin (20 mg/d administered orally at 8:00 PM). All studied parameters, including (1) survival at 1 year, (2) the free-from-brain-progression period, and (3) mean survival time, were significantly higher in patients treated with melatonin than in those who received the supportive care alone. The authors concluded that "the pineal hormone melatonin may be able to improve the survival time and the quality of life in patients with brain metastases due to solid tumors." 42 Colorectal cancer. In 1995, Lissoni's group published a study on the effects of immunotherapy with IL-2 and melatonin versus supportive care alone in the treatment of patients with metastatic colorectal cancer that was no longer responsive to the standard 5fluorouracil-based chemotherapy of the time. 43 Several years later, a new drug, CPT-11 (irinotecan), was approved as a second-line chemotherapy for colorectal cancer. Their group then evaluated the use of this drug, with or without melatonin, in the treatment of colorectal cancer. 44 This study included 30 patients whose metastatic colorectal cancer had progressed despite at least 1 previous chemotherapeutic regime containing 5-fluorouracil. These patients were randomized to be treated with CPT-11 alone or CPT-11 plus melatonin. All patients received a weekly lowdose schedule of CPT-11, given intravenously at 125 mg/m 2 /wk for 9 consecutive weeks. Melatonin was administered orally at 20 mg/d during the dark period of the day. No complete response was observed. However, a partial response was achieved in 2 of 16 patients treated with CPT-11 alone versus 5 of 14 patients also treated with melatonin. Moreover, stable disease was obtained in 5 of 16 patients treated with CPT-11 alone but in 7 of 14 patients treated with CPT-11 plus melatonin.
Therefore, the degree of disease control achieved in patients who were concomitantly treated with melatonin was nearly double that of patients who received chemotherapy alone: 85.7% versus 43.8% in those treated with chemotherapy alone. The authors reasonably concluded that "the efficacy of weekly lowdose CPT-11 in pretreated metastatic colorectal cancer patients may be enhanced by a concomitant daily administration of the pineal hormone MLT [melatonin]." 44(p1951) Metastatic colon cancer. In the mid-1980s, IL-2 was much in the news as a high-dose (but also very toxic) treatment for renal cell cancer and melanoma. 45 It was not known as an effective treatment for colorectal cancer or other kinds of malignancy. However, according to Lissoni, melatonin was able to amplify the effects of IL-2, which allowed it to be given at lower, and therefore less toxic, doses. Lissoni's group performed a clinical trial to evaluate the impact of low-dose IL-2 plus melatonin on the survival time in metastatic colon cancer, which had progressed following treatment with 5-FU plus folates. The study included 50 patients. Patients were randomized to receive either supportive care alone or else low-dose subcutaneous IL-2 (3 million IU/d for 6 d/wk for 4 weeks) plus melatonin (40 mg/d orally).
No spontaneous tumor regression occurred in patients receiving supportive care alone. However, a partial response was achieved in 3 of 25 (12%) patients treated with combined immunotherapy. After 1 year, there were 9 of 25 (36%) patients still alive in the treatment group versus 3 of 25 (12%) in the control group, a 3-fold increase that was statistically significant (P < .05).
"This study suggests that low-dose subcutaneous IL-2 plus melatonin may be effective as a second-line therapy to induce tumor regression," Lissoni wrote, "and to prolong percent survival at 1 year in metastatic colorectal cancer patients progressing under 5-FU and folates." 43(p243) 
Cartesian Therapy
In retrospect, the use of high doses (10-40 mg/d) of melatonin as a cancer treatment seemed valuable but limited. It generally increased the response rate and extended survival, but it was not "the cure" by any means. While on the right track, some further development was clearly needed to make a conceptual breakthrough. Pondering the meaning of 2 decades' worth of test results, Lissoni came to the conclusion that cancer resulted not from a lack of melatonin per se but from a profound disruption in the endocrine system, particularly the pineal gland. In 2003, he and his colleagues further refined the melatonin concept when they introduced experimental treatment with total pineal endocrine substitute therapy (TPEST). 46 Melatonin is not the only pineal hormone, nor is it the only one responsible for the antitumor activity of the pineal gland. In fact, there are other pineal indoles whose inclusion in a comprehensive replacement schedule may also exert an anticancer effect. Three of these other indoles are 5-methoxytriptamine (5-MTT, or mexamine), 47 5-methoxytryptophol (5-MTP), 48 and 5-methoxyindole acetic acid (5-MIA). 49 (There probably are many others yet undiscovered, Lissoni told me.) According to Lissoni, cancer progression is associated with a concomitant overall decline in pineal endocrine function, not just the production of one hormone. Therefore, the replacement of full pineal function in advanced cancer patients would require not just melatonin but the exogenous administration of the 4 known pineal indoles.
In earlier work, melatonin alone induced a control of neoplastic progression in about 30% of untreatable metastatic solid tumor patients. Lissoni's 2003 study of TPEST attempted to evaluate the effectiveness of treatment using these 4 known pineal indoles. This pilot study included just 14 patients with metastatic solid tumors who had failed to respond to conventional anticancer therapies. The 4 pineal indoles were given orally according to a schedule that was elaborated in an attempt to reproduce the circadian rhythms involved in their secretion. Thus, 20 mg/d of melatonin was given during the night. In addition, 1 mg/d of the other indoles was administered: 5-MIA in the morning, 5-MTP at noon, and 5-MTT in the afternoon.
Despite the advanced nature of these patients' illnesses, disease control was achieved in 9 of 14 (64%) patients. This consisted of a partial response in 1 patient and stable disease in 8 others. The median time of disease control (partial response + stable disease) was 6 months (range, 4-10 months). Since this was a phase II study, there was no control group. But as a preliminary study, it showed that total pineal endocrine replacement therapy could induce a measure of disease control in 60% of otherwise untreatable patients. These results were approximately twice as good as with melatonin alone and indirectly confirmed that in humans, melatonin is not the only hormone responsible for the anticancer property of the pineal gland. The results also underscored the importance of circadian rhythms as a potentiator of biological and therapeutic responses.
The French philosopher René Descartes (1596-1650) famously suggested that the pineal gland was that part of the body with which the soul was most immediately associated. 50 In recognition of this genius' shrewd, but essentially intuitive, divination of the pineal gland's central role in the endocrine orchestra, Lissoni and his group have dubbed their TPEST "Cartesian therapy."
Psychological and Spiritual Dimensions
When Lissoni speaks about cancer these days, it is more about the psychological and the spiritual aspects of the disease than just the physical. His prolonged investigation of the neuroendocrine manipulation of cancer growth has led him, he believes, to a deeper level of understanding concerning the pathophysiology of cancer. His research efforts are increasingly focused on the interface between neuroendocrine pathways and the elusive human psyche.
A turn toward psychooncology, even spirituality, will not come as a surprise to those who know him personally. For this distinguished cancer scientist is also a published poet, the author of Le Due Bianche Colonne del Mondo (The Two White Columns of the World), which was published in 1990. Many of the poems in this collection were inspired by Lissoni's trips to Greenland and the South Pole and concern spiritual or religious themes.
Psychooncology, Lissoni points out, is generally limited to investigations into the psychological status of cancer patients. Historically, it has been less concerned with questions of how changes in mental status are linked to alterations in the function of the endocrine glands. (One representative psychooncology text, for example, has no references to either melatonin or the pineal gland. 51 ) In contrast, Lissoni has deliberately focused on exactly this kind of change as an expression of underlying pathology, describing it as "a progressive decline in the pineal endocrine function and an anomalous activity of brain opioid system." 55(p50) As an illustration, he has pointed to the anticancer effect of apomorphine, a dopaminergic agent. Epidemiological studies (done at the NIH 52 ) have shown that people with Parkinson's disease have lower rates of breast and other types of malignancies. Since nearly all Parkinsonian patients are treated with the drug L-DOPA (L-β-3,4-dihydroxyphenylalanine) or analogous substances, the possibility exists that this and related therapeutic agents can influence cancer risk. Scientists at the University of Pisa have studied the antiproliferative effect of these agents on Chinese hamster ovary-K1 cell growth. Among the compounds tested, apomorphine proved to be the most potent inhibitor of this cell's growth. 53
Pleasure Principle
For example, dopaminergic sensitivity, says Lissoni, is involved in pleasure-related neurochemical mechanisms. He and his colleagues therefore began a clinical study "to analyze the endocrine response to apomorphine in metastatic cancer patients." The larger agenda, however, was to investigate "pleasurerelated neuroendocrine mechanisms in human neoplasms." Is the "pleasure principle" (as Freud called it) involved in the onset and progression of cancer? Half a century ago, this line of reasoning was pursued by one of cancer history's most controversial practitioners, Freud's disciple Wilhelm Reich, MD. 54 Lissoni has proposed revisiting this question equipped with scientific tools that were undreamed of in Reich's day.
In another pilot experiment, 10 men with various kinds of metastatic cancer were studied, while 6 men without known cancer served as a control group. Apomorphine was given orally at 0.01 mg/kg body weight in the morning, and venous blood samples were then collected before and at 20, 60, and 120 minutes after apomorphine administration. The endocrine analysis consisted of the measurement of serum levels of growth hormone (GH), prolactin (PRL), and cortisol (the major adrenal glucocorticoid).
All the cancer patients, Lissoni reported, had alterations involving 1 or more of their endocrine responses to apomorphine. For instance, mean GH and cortisol levels after the administration of apomorphine were significantly higher in controls than in cancer patients (no substantial difference in PRL levels could be detected between the 2 groups).
This preliminary study showed that these metastatic cancer patients exhibited an altered endocrine response to the drug apomorphine. It suggested that cancer progression may be associated with an altered dopaminergic sensitivity.
This study may help to illuminate certain fundamental questions of human psychology because the dopaminergic system is central to pleasure-related neurochemical mechanisms. Whether this relationship is one of cause and effect remains to be seen, but Lissoni suggests that a "decline in the perception of pleasure with cancer progression may depend not only on psychological factors, but also, at least in part, on psychochemical alterations occurring during the clinical course of the neoplastic disease." 55(p50) Lissoni's first paper on this topic appeared in early 2003. Since then, he and his colleagues, including Giusy Messina, a psychologist at his hospital, have prepared an even more provocative paper. According to an Italian preprint he showed me, it extends these findings into new and uncharted territory. Lissoni has been giving standard Rorschach personality tests to cancer patients in an attempt to explore the psychic dimensions of their medical problem. He claims to have found that in approximately 85% of cases, cancer is preceded by the simultaneous suppression of what he terms psychic sexuality (sessualita psichica) and of spirituality. This dual suppression of the mental/ spiritual states leads, he says, to the immunosuppression of the normal anticancer immune response (della risposta immunitaria antitumorale), accompanied by changes in the psyche. Of course, it is to be expected that patients with advanced cancer should be preoccupied with their disease. But in Lissoni's study, the loss of sexual interest and of spiritual dimensions occurs even among those in the earliest-and often asymptomatic-stages of cancer. It does not appear to be the result of the patient learning that he or she has cancer; rather, suggests Lissoni, the relationship is causative in nature.
Although Lissoni seems convinced of the predictive value of such tests, it will certainly take a great deal of rigorous study to convince his fellow oncologists of this. A psychological causation of tumors has been postulated since the days when the Greco-Roman physician Galen spoke of a link between breast cancer and melancholia (through the medium of the darkest of the four "humors," black bile). However, psychological causations, although frequently suspected, have been exceedingly difficult to prove with sufficient rigor to convince those who adhere to a predominantly biochemical model of disease. Some of the fundamental, and as yet unanswered, questions are these: Is the Rorschach test a valid indicator of mental state? How does one measure the "loss of sexuality"? What exactly is the "loss of spirituality" and how does one measure such a subjective state? And, above all, how can one be sure that the loss of these mental states precedes the diagnosis of cancer rather than being caused by a worried preoccupation with cancer (even in its earliest stages)?
The other surprising departure in Lissoni's previously physiologically based research has been his therapeutic use of Himalayan Bach flower remedies as a way of overcoming the perceived repression of sexual and spiritual elements in the psyche of cancer patients. In particular, Lissoni has pointed to the use of a flower called Meenalih, whose scientific name has proven difficult to pin down. At Web sites promoting this treatment, it is described as being indicated for religious or self-righteous people who repress their sexuality, as they feel it is wrong or sinful. For impotence caused by guilt about one's body, and the pleasure that sexual urges bring. It transforms old fearful attitudes of guilt that keep such repression in place. It teaches that true virtue lies in real love, which embraces everything, and that we have the right to a pleasurable and enjoyable life, and that sex is an important part of it. 56 It is an interesting concept to try to correct the putative effects of sexual repression through the most subtle of flower essences. (To create Himalayan Bach remedies, the flower is not even plucked, but a stream of water is simply directed over it.) The idea that this could have any effect at all on either sexuality or cancer will of course be greeted with skepticism, and Lissoni may have a difficult time convincing his colleagues of the utility of such subtle plant essences.
Lissoni mentioned that there were 2200 oncologists in Italy but that so far not one has adopted his methods or embraced his results, even the biochemically well-defined ones on melatonin. He has called for a "new pathophysiology of cancer," but it is a call that few have heeded. Most Italian oncologists, he said, treat cancer without establishing a clear definition of the overall physiological changes that are taking place in their patients.
A Visit to Bologna
My next stop was at the Immunotherapy Module, Department of Urology and Nephrology, S. Orsola-Malpighi Hospital, in Bologna, Italy. The director of that unit is Giancarlo Pizza, MD. Dr Pizza was born in Latina, Italy, in 1946 and graduated from the University of Bologna as a doctor of medicine in 1972. He has a broad medical background and is licensed as a specialist in public health, allergy/clinical immunology, and urology. He is a member of the Italian Society of Urology and Urological Oncology. For his entire ca-reer, he has been affiliated with this 1500-bed hospital. He is presently the chief of the Immunodiagnosis and Immunotherapy Unit in the hospital's First Division of Urology. He has also been a visiting scientist at the NIH and at Mt. Sinai Hospital in New York, New York.
Like Lissoni, Pizza is well published. He is the author of 101 scientific publications and 62 abstracts and meeting presentations, and he has been a speaker at 47 congresses and 9 seminars. Also like Lissoni, he neither has, nor seeks, private patients but works entirely within the framework of Italy's national medical system. In other words, he has no financial incentive to give, or withhold, any particular treatment. He feels that this gives him an objectivity that is sometimes lacking in those who treat patients privately. Pizza has around him a small team of associates. His closest collaborator is his wife, Caterina de Vinci, MD. (By coincidence, as a medical student in Modena, she studied under Di Bella. One gets the feeling that innovative oncology in Italy is a small world indeed.)
Pizza's approach is a purely immunotherapeutic one. What makes him controversial in American terms is his career-long interest in transfer factor (TF), a polypeptide secreted by lymphocytes that is capable of transferring immunity from one cell to another.
TF was discovered by Henry Sherwood Lawrence, MD, while at the Infectious Disease and Immunology Unit of New York University Medical Center, New York. Starting in 1949, Lawrence took lymphocytes from an individual who had signs of immunity against Mycobacterium tuberculosis (ie, who had a positive skin test against tuberculin) and then injected them into a recipient who did not react against tuberculin. By doing so, Lawrence was able to make the second person as reactive as the first. He had somehow transferred immunity with the white blood cells. He later was able to make an extract of white blood cells that accomplished the same thing.
Lawrence dubbed the agent transfer factor, although he had little idea of its nature in either chemical or immunological terms. The limited state of knowledge in the late 1940s and early 1950s regarding the human immune system made any understanding of this startling phenomenon impossible to achieve. Not surprisingly, there were those who questioned TF's very existence. Over the next few decades, even those who believed in TF's existence routinely called it "curious," "unique," "mysterious," 57 -in other words, an "enigma." 58 TF was a prime example of an empirical finding, which outran the conceptual understanding available at the time. It was greeted skeptically, until at least further discoveries make its mechanism of action more plausible.
In the late 1950s, Robert A. Good, MD, PhD (later president of Sloan-Kettering Institute, New York) and others, studied the ontogeny and phylogeny of immune responses in animals, in particular, the formative role of the thymus gland and the avian bursa of Fabricius in processing lymphocytes. On the basis of this understanding, Good correctly postulated the existence of 2 principal subsets of lymphocytes in humans, which came to be known as the Blymphocytes (processed primarily in the spleen and bone marrow) and T-lymphocytes (processed in the thymus gland). B cells and T cells were involved, respectively, in antibody-mediated immunity and cellmediated immunity. This began to be of interest to cancer researchers since a growing body of data suggested that cell-mediated immunity had a major role in preventing the development and spread of cancer.
But the same T-cell lymphocytes were also involved in delayed hypersensitivity reactions. This raised an interesting possibility: if one form of TF could confer a recognition of microbial antigens on those whose own exposures had not created such sensitivity, then perhaps the same or another form could convey a resistance to cancer cells if transferred from cancer-free individuals to those suffering from the disease? (Subsequent research has shown that there are in fact many different types of antigen-specific transfer factors.)
Because of the persistent difficulty in defining the chemical composition of TF, interest has tended to decrease, rather than increase, over the years. For example, there were nearly half as many MEDLINElisted articles on the topic in the 1990s (406) than there were in the 1970s (774). In fact, TF might have fallen into total obscurity had it not been for the activity of Professor H. Hugh Fudenberg, MD, and his colleagues. From 1966 to 1975, Fudenberg was professor of medicine at the University of California School of Medicine in San Francisco and professor of bacteriology and immunology at the University of California, Berkeley. 59 A prodigious researcher, his bibliography now includes more than 800 peer-reviewed publications.
Starting in 1970, Fudenberg began to publish his research on TF, eventually extending the range of its clinical applications. 60 Fudenberg was the first to show that leukocyte extracts, produced through dialysis, could initiate a variety of cell-mediated immune reactions, including the inhibition of macrophage migration. Despite these fruitful observations, the mechanisms of action of TF and its potential usefulness in modulating immune function remained poorly understood until at least the late 1980s. 61 In 1989, Silverberg's history of immunology still could state that "little progress has been made in elucidating the mechanism of information carriage or of information transfer to the recipient of this unique passive transfer system." 57(p237) Part of the controversy about the importance of TF was due to confusion over terminology. It was Pizza, in collaboraton with Fudenberg, who first proposed that the term transfer factor should be used only to describe those components of lymphocyte extracts that resulted in the transfer of T-lymphocyte responses in an antigen-specific manner. 62 While TF's precise mechanism of action is still not completely understood, it appears to act at the molecular level by influencing DNA polymerization. 63 Most of Pizza's work has been on cancer, and specifically on cancers of the genitourinary system. But together with his colleagues (including Fudenberg), he has used TFs, or related substances, as experimental treatments for infantile-onset autism, 64 HIV/ AIDS, 65 chronic fatigue syndrome, 66 Alzheimer's disease, 67 and other illnesses. This work has been carried out in a rigorous scientific fashion. However, not everyone promoting TF has had such scruples or had as their chief motivation the promotion of human knowledge and well-being.
Internet Schemes
TF came to public prominence in the United States during the 1990s, when a southern Minnesota dairy farmer, Herbert Saunders, offered pregnant cows for sale to people with advanced chronic diseases of various sorts. The patient would have a test tube of blood drawn, and this blood was then injected into the pregnant cow's udder. After the cow calved, the patient would drink the cow's antibody-rich colostrum in the form of whey. Saunders characterized this unusual oral treatment as a form of "transfer factor." This treatment became well known after Representative Berkley Bedell, a 6-term congressman from the neighboring state of Iowa, reported that it cured him of his Lyme disease-related arthritis. During the 1990s, Saunders was unsuccessfully prosecuted several times by the state of Minnesota. 68 This controversy erupted, fortuitously, at the same time as the World Wide Web emerged as a medium for the mass dissemination of information on nonconventional medical treatments. As a result, there are presently more than 50,000 Web sites offering information on TF. Some offer for sale "a concentrated blend of chicken-derived transfer factors and bovine colostrum extract." It is crucial to realize that the great majority of these products are sold for self-administered oral consumption, as a kind of food supplement, whereas the TF prepared and administered in Pizza's clinic is in an injectable and scientifically standardized form.
Promotional Web sites routinely promise that their TF will "super-charge your immune system," combat fatigue, restore sexual potency, and so forth. They claim furthermore that TF will "fight infections and diseases such as SARS and West Nile, and the increased threat of Bio-Terrorism." TF is "the most important product ever introduced," according to a spokesperson for one of these products (R. Robertson, spokesperson for Transfer Factor Plus, oral communication, January 23, 2004) . Others offer "homebased income opportunities," if one joins multilevel marketing schemes to sell TF aggressively to one's friends and neighbors. It is a scene reminiscent of the charlatans and mountebanks of olden times! To the casual observer, then, TF might look like an unsubstantiated treatment that is being sold without adequate testing to exploit the desperation of people with a variety of diseases, including cancer. It may be because of fears of premature commercialization that there is no mention of this potentially promising treatment in any of the major cancer textbooks, including DeVita et al's Cancer: Principles and Practice of Oncology. 69 However, we must underline the fact that there are 2 worlds of TF. In contrast to the Internet promotions, injectable TF, properly prepared, is the focus of genuine scientific interest, the subject of almost 2000 MEDLINE-listed articles, more than 150 of which refer to clinical trials.
Pizza's Protocol for Metastatic Renal Cell Carcinoma
Pizza's current protocol for metastatic renal cell carcinoma (MRCC) consists of 1 monthly intralymphatic injection of IL-2 and lymphocyte-activated killer (LAK) cells. This comes after 3 consecutive days of IL-2 inhalation. Patients also receive intramuscular injections of TF monthly and interferon-α biweekly. The initial treatment cycle lasts 6 months, with restaging at 3 and 6 months. If the disease is put into complete remission, then an additional 6-month cycle is initiated as a preventive measure. Similarly, persistent disease is also followed by an additional 6-month cycle in an attempt to initiate a response. In cases of progression, however, the treatment is discontinued, unless the patient expresses a desire to pursue it, in which case she or he is given an additional cycle. All patients are included in the ongoing statistical analysis. 70 The results from April 1986 to September 2000 were as follows: 122 MRCC patients were treated. Adverse effects were negligible. There were complete responses in 11 and partial responses in 13 patients, for a total response rate of 19.7%. Of the 24 responding patients, 17 resumed progression, whereas 7 remained in remission 11 to 69 months later. The overall median survival of treated patients (28 months) was 3.5-fold higher than the median survival of historical controls (7.5 months). A Kaplan-Meier curve showed 25% survival 11 years after the beginning of immunotherapy. The addition of IL-2 by inhalation appeared to improve survival.
The authors concluded that the present immunotherapy protocol appears to be efficacious, safe, devoid of adverse side effects, far less costly than others and able to offer a good quality of life to MRCC patients. If confirmed in a multicenter trial, it could set the basis for developing low-cost immunomodulatory treatments. 70(p109) The latter point is important in an era of increasing cost consciousness in medicine. At Pizza's clinic, all costs are covered by government health insurance, and they are very reasonable. Initiating the treatment costs 77 Euros. The first visit is 18 Euros. Administering LAK is 22 Euros, and so forth. This is at a time when private clinics in other countries may charge $50,000 or more for experimental cancer immunotherapy.
Pizza's protocol is a treatment that amply deserves further study, and in fact an American group, the Cancer Treatment Research Foundation of Arlington Heights, Illinois, is funding a phase I/II study in conjunction with Columbia University, New York, using TF and intralymphatic IL-2 in patients with stage D3 prostate cancer. 71 But whether such a protocol, so inexpensive to produce and administer, with many of its components in the public domain and therefore unpatentable, can survive in today's competitive marketplace remains to be seen.
Santa Famiglia Conference and LSA-CM
My third destination was Casa di Cura Santa Famiglia (Santa Famiglia Hospital) on the Via dei Gracchi in Rome for a conference titled "An International Day of Study on Prevention in Oncology: Present and Future Developments" (November 13, 2003) . The event was hosted by Massimo Bonucci, MD, chief of the Pathological Anatomy Service at this gynecological diagnosis and treatment center, which is affiliated with the University of Rome. Bonucci, who is also an oncologist, is an ardent proponent of integrating complementary methods into cancer care. I first met him almost 6 years ago at a "Medicine Week" in Baden-Baden, and we have kept up a lively correspondence since then. It was at his invitation to visit him in Italy that initiated this whole journey.
Bonucci was particularly interested in the work of the late Hans Nieper, MD, director of the Paracelsus Klinik in Hannover and founder of the German Oncology Society. More recently, he has joined the board of a nascent organization, the International Medical Research and Consulting Foundation, based in Berg, Germany. The director of that foundation, Dana Flavin-Koenig, MD, also spoke at the Rome meeting.
Here, I would like to focus on the presentation of a colleague of Bonucci, Aldo Mancini, MD, who is chief of experimental oncology at the Ospedale Pascale, Naples, and an associate of the Fondation Pascale of the Italian National Cancer Institute. Mancini has not yet published some of the clinical data he presented. His presentation (simultaneously translated into English by an Italian-American urologist, Louis Mauro, MD) was on certain cancer proteins that are being developed as both a therapy and as a preventative. The essential feature is that this is a novel cancer cell line, named LSA, that has been isolated from a human liposarcoma. These cells have both morphological and biochemical features that strongly resemble adipocytes (fat-storing cells found mostly in the abdominal cavity and subcutaneous tissue). When grown in a conditioned cell-growth medium (a modification of the standard F12 medium), these liposarcoma cells confer both cytostatic and cytotoxic effects on the medium, which then becomes a potential therapeutic agent.
LSA-CM (ie, the culture medium of LSA cells) appears to induce both apoptosis and cell necrosis and is also associated with a downregulation of c-myc and the upregulation of p53 in several human cancer cell lines (breast, lung, glioblastoma, etc). A toxicity analysis of LSA-CM, performed in 3 different animal species, showed that this new therapeutic substance is absolutely free of acute, subacute, and chronic toxicity.
According to a limited amount of published work, the MCF-7 human breast cancer cell line and also glioblastoma cells are killed by LSA-CM in 5 to 6 days. However, these same cells are killed in just 30 hours by LSA-CM that has first been co-incubated with low doses of the standard chemotherapeutic drug cisplatin. LSA-CM therefore has promise not only as monotherapy but also as an adjunct to low-dose cisplatin chemotherapy. 72 In experiments on mice with mammary tumors (Balb-c-fc3H), Mancini has been able to demonstrate that LSA-CM delivered for 15 days through peritumoral injections resulted in the rapid disruption of existing malignant growths and the prevention of metastases. By contrast, in untreated controls, tumor masses were 4 times larger than the initial lesions, and numerous metastases were found in the lungs.
From the LSA-CM, Mancini and his coworkers isolated a protein that expressed this cytotoxic activity. This protein was specific and selective only for tumor cells that express estrogen receptors. Amino acid sequencing revealed that it was in fact a mutated form of manganese super oxide dismutase (Mn-SOD-2).
These results have also been confirmed by using a form of recombinant Mn-SOD-2 that is expressed in E. coli. As a free radical scavenger, Mn-SOD-2 may also be useful in the prevention of ischemic injury (A. Mancini, personal communication, February 2, 2004) . Having been patented internationally, the substance is now in toxicological testing by Fidia, Italy's fourth-largest pharmaceutical company. 73 Although still in an early stage of development, the use of Mn-SOD-2 (with or without chemotherapy) could be an exciting departure from standard toxic treatments. Mancini is performing in vitro and in vivo tests, and phase I/II clinical trials have already been approved in Italy. Mancini is eager to find international colleagues who wish to further develop this exciting concept and, along with Bonucci, to foster the development of a truly integrative form of oncology in Italy (A. Mancini, personal communication, February 2, 2004).
Conclusions
Cancer is a problem of considerable gravity in Italy, just as it is in other industrialized countries. There are elements of the Italian lifestyle that are conducive to low cancer incidence and mortality rates, such as the legendary Mediterranean diet, with its outstanding wine and olive oil. However, the country is also pulled in the opposite direction by high tobacco and saturated fat consumption and an increasing reliance on American-style fast food restaurants. It is thus a study in contrasts. 74 The present government's underfunding of science is reflected in its poor showing in most international ratings for various objective markers of progress. Although Italy's gross domestic product is the seventh-largest in the world, 75 this country is clearly not investing a proportionate share of its wealth in science, technology, or higher education. According to the Global Competitiveness Report (a cross-country comparison of information relating to innovation and growth), in 2003, Italy ranked 41st in the world in a cumulative measurement of these areas; in particular, it ranked 25th in innovation, 26th in "networked readiness," and 39th in the technology index. 76 In mathematical and scientific literacy, it ranked 23rd. In 2002, Italy ranked only 28th in the number of Internet hosts per 10,000 population and 21st in the percentage of both Internet users and the number of PCs in the population. In 2002, only about 30% of Italians had access to the Internet, about half the proportion of the Scandinavian countries, the United States, or South Korea. (I stayed at nearly a dozen Italian hotels, yet in only 1 did I find Internet access.) Finally, when it comes to knowledge of English, the "lingua franca" of science, Italy ranks 22nd in standardized test scores, behind poorer countries such as Poland and Greece. 77 None of these statistics bode well for the future of scientific progress in this birthplace of modern medicine. There has not been an Italian winner of the Nobel Prize for Physiology or Medicine in 18 years, since Rita Levi-Montalcini won it in 1986. 78 The availability of free or low-cost medical care means that all Italians can get treatment for cancer and other serious diseases-itself no small achievement. However, the dominance of the conventional medical paradigm limits the choices that are available through the state hospital system. It has been the remarkable accomplishment of the clinicians reviewed here to introduce some flexibility into this rigid system and to offer their patients innovative treatment options. This has been an uphill struggle, strewn with many bureaucratic roadblocks. The fact that they have succeeded at all is a testament to the innovative sprit of Leonardo da Vinci, which, 5 centuries later, lives on in the land of his birth.
